Boston Scientific stock falls as cyberattack forces 2026 guidance rethink

Boston Scientific stock (ISIN US10117L1017) is trading far below last year’s peak after management warned in mid September 2026 that a major cyberattack will materially impact third quarter and full-year 2026 results and make it unlikely the company will reach its previously guided net sales growth and adjusted EPS ranges.

Cyberattack forces 2026 guidance rethink

According to Stocktwits on September 19, 2026, Boston Scientific disclosed that a cyber incident identified on August 25, 2026 caused a network outage that limited access to operating systems and business applications, disrupting manufacturing and the processing and shipment of customer orders worldwide.

As Stocktwits reports, the medical device maker had previously forecast full-year 2026 net sales growth of 5.5 percent to 6.5 percent from revenue of USD 20.07 billion in full-year 2025 and adjusted earnings of USD 3.28 to USD 3.32 per share versus USD 3.06 per share last year, but now expects to fall short of these ranges because of the attack.

In the same update, Boston Scientific said it expects to provide revised full-year 2026 guidance together with its third quarter 2026 results on October 28, 2026, giving investors a defined date when management will quantify the earnings hit and outline its recovery plan.

Operational recovery and backlog implications

According to Stocktwits, the company stated that its distribution network has been substantially restored by mid September 2026, with major centers processing and shipping orders at or above normal levels, and sterilization facilities back online, while manufacturing has resumed across most global facilities.

The company also indicated it expects to recover some of the revenue deferred by the disruption as it works through order backlogs, but stressed that the full financial impact for 2026 remains uncertain and that the timeline for a complete operational recovery of all systems is not yet known, a risk factor investors must weigh against the long term demand for its cardiovascular and other interventional products.

As Stocktwits notes, Boston Scientific had previously expected third quarter 2026 sales to grow between 3 percent and 5 percent compared with third quarter 2025 revenue of USD 5.07 billion, a benchmark that now serves as a historical reference rather than a current target in light of the cyber incident.

Share price and valuation after steep decline

Boston Scientific stock has sold off sharply since the cyberattack became public, with Stocktwits reporting that the shares were trading more than 5 percent lower on the day of the guidance warning and had declined around 9 percent since the incident was first disclosed.

As a separate valuation overview from GuruFocus on September 18, 2026 highlights, Boston Scientific shares were trading around USD 43.55, which the platform’s GF Value metric estimates to be approximately 59.4 percent below an intrinsic value of USD 107.28, implying a wide gap between market price and fundamental valuation despite the operational headwinds.

According to GuruFocus, Boston Scientific’s share price has fallen about 54 percent year to date in 2026, placing it among the large cap United States healthcare stocks with the steepest declines and earning it a low momentum grade, while still scoring a GF Score of 80 out of 100 on profitability and growth metrics.

Key fundamental baseline for 2025 and 2026

As Stocktwits summarizes, Boston Scientific generated revenue of USD 20.07 billion in full-year 2025 and reported adjusted earnings of USD 3.06 per share for that year, figures that serve as the baseline for the original 2026 guidance ranges now under review.

For full-year 2026, the company had issued a sales growth outlook of 5.5 percent to 6.5 percent versus 2025 revenue and guided for adjusted EPS of USD 3.28 to USD 3.32 per share, implying an earnings increase of roughly 7.2 percent to 8.5 percent compared with the prior year’s USD 3.06 per share before the cyberattack disruption.

The fact that management now expects net sales growth and adjusted EPS to come in below these ranges because of the network outage underscores that the cyber incident is not merely an operational nuisance but a material financial event, even if the long term demand environment for minimally invasive therapies remains intact.

Risk factors and investor focus ahead of October 28

For investors, the main near term risk is that the company’s assessment of the cyberattack’s impact could still change as it completes forensic work and restores all systems, potentially causing further volatility in Boston Scientific stock if the revised guidance on October 28, 2026 posits a deeper revenue or margin hit than currently expected.

Another factor highlighted by GuruFocus is insider activity, with net selling of approximately USD 29.3 million worth of shares versus USD 10.0 million bought over the past 12 months, alongside positions held by 19 so called premium gurus, 12 of whom have recently added and 9 trimmed, indicating a mixed but engaged institutional investor base.

In the medium term, the ability of Boston Scientific to clear backlogs, restore its manufacturing footprint fully and protect its reputation with hospital customers will be central to whether revenue growth in 2027 and beyond can realign with the high single digit trajectory implied by its pre attack guidance.

Boston Scientific stock price snapshot

Per recent New York Stock Exchange data cited by major financial portals, Boston Scientific stock last closed around USD 43.34 on NYSE on September 18, 2026, with an after hours indication near USD 43.47, leaving the shares close to the lower end of a 52 week range that spans roughly USD 42.20 to USD 105.65 and reflecting elevated trading volumes of about 24,627,489 shares over that period.

More news and analyses on Boston Scientific stock